Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
ETV6 encodes an ETS family transcription factor. Additionally we are shipping ETV6 Proteins (5) and ETV6 Kits (2) and many more products for this protein.
Showing 10 out of 111 products:
Human Polyclonal ETV6 Primary Antibody for ICC, IF - ABIN4309682
Noetzli, Lo, Lee-Sherick, Callaghan, Noris, Savoia, Rajpurkar, Jones, Gowan, Balduini, Pecci, Gnan, De Rocco, Doubek, Li, Lu, Leung, Landolt-Marticorena, Hunger, Heller, Gutierrez-Hartmann, Xiayuan et al.: Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. ... in Nature genetics 2015
Show all 2 Pubmed References
Human Monoclonal ETV6 Primary Antibody for IHC (p), ELISA - ABIN560810
Meester-Smoor, Janssen, ter Haar, van Wely, Aarnoudse, van Oord, van Tilburg, Zwarthoff: The ETS family member TEL binds to nuclear receptors RAR and RXR and represses gene activation. in PLoS ONE 2011
Show all 2 Pubmed References
Dominant-negative truncated ETV6 with deletions of the ETS (show ETS1 Antibodies) domain or the PNT (show ETS2 Antibodies) domain interfered with repression by full-length ETV6 and affected expression of early hematopoietic and erythroid markers in embryos.
the transcriptional repressor Tel plays an evolutionarily conserved role in angiogenesis: it is indispensable for the sprouting of human endothelial cells and for normal development of the Danio rerio blood circulatory system
Report ETV6-rearranged low-grade sinonasal adenocarcinomas.
will also provide an overview of common clinical features as well as recommendations for patient screening and follow-up and will debate whether additional clinical features should be included with the germline ETV6 syndrome[review]
The clinical significance of ETV6-RUNX1 (show RUNX1 Antibodies).
Deliver the necessary promotional drive for the progression of ETV6-RUNX1 (show RUNX1 Antibodies)+ pre-leukaemic cells.
Data suggest that, for ETV6 (which harbors only a single DNA contact interface for both specific and nonspecific interactions), intersegmental jumping represents a major molecular event that significantly modifies the thermodynamics and kinetics of DNA target search; site-specific DNA binding by ETV6 involves a kinetic intermediate at the cognate sequence.
Our findings suggest ETV6-RUNX1 (show RUNX1 Antibodies) is associated with space-time clustering of childhood leukemia (CL) and are consistent with an infection interacting with that oncogene (show RAB1A Antibodies) in early life leading to clinical leukemia.
EGFR (show EGFR Antibodies) activation leads to the induction of miR (show MLXIP Antibodies)-96 expression and suppression of ETV6, which contributes to prostate cancer progression.
we demonstrate the expression of the ETV6-NTRK3 fusion (show NTRK3 Antibodies) oncogene (show RAB1A Antibodies) in a small subset of inflammatory myofibroblastic tumors
ETV6-NTRK3 (show NTRK3 Antibodies) translocated papillary thyroid carcinomas are locoregionally aggressive and can metastasize distantly.
We report 6 cases of secretory carcinomas of the skin harboring the ETV6-NTRK3 (show NTRK3 Antibodies) gene fusion
Together with similar observations made in human PAX5 (show PAX5 Antibodies)-ETV6(+) B-ALLs, these data identified PAX5 (show PAX5 Antibodies)-ETV6 fusion as a potent oncoprotein that drives B-cell leukemia development.
ETV6 DNA binding inhibition is established by the stability of its inhibitory helix
Studied the combination of Etv6-RUNX1 (show RUNX1 Antibodies) and Pax5 (show PAX5 Antibodies)(+/-) alleles, they generated a transplantable B220 (show PTPRC Antibodies) + CD19 (show CD19 Antibodies)+ B-ALL with a significant disease incidence; RNA-seq analysis showed a gene expression pattern consistent with arrest at the pre-B stage.
In murine models of B-cell progenitors, evidence found that ETV6- RUNX1 (show RUNX1 Antibodies) alters the expression of cytoskeletal regulatory genes, resulting in a block of the CDC42 (show CDC42 Antibodies) signaling pathway, and compromises the chemotactic response to CXCL12 (show CXCL12 Antibodies).
ETV6-SAM (show TTN Antibodies) domain interface mutations block ETV6-NTRK3 (show NTRK3 Antibodies)-induced cellular transformation
the autoinhibition of ETV6 DNA binding by sequences C-terminal to its ETS (show ETS1 Antibodies) domain
find that both IRS1 (show IRS1 Antibodies) and kinase active IGF1R (show IGF1R Antibodies) are required for ETV6-NTRK3 (show NTRK3 Antibodies) transformation, that tyrosine phosphorylated IRS1 (show IRS1 Antibodies) is present in high molecular weight complexes with EN and IGF1R (show IGF1R Antibodies), and that EN colocalizes with IGF1R (show IGF1R Antibodies) at the plasma membrane
Cytogenetic study of 33 children with ETV6-RUNX1 (show RUNX1 Antibodies) positive acute lymphoblastic leukemia predict long term survival.
TEL binding to IRF-8 (show IRF8 Antibodies) for recruitment of HDAC3 (show HDAC3 Antibodies) is regulated by gamma-interferon (show IFNG Antibodies)
the ability of TEL to repress transcription and suppress growth is regulated by sumoylation and nuclear export
This gene encodes an ETS family transcription factor. The product of this gene contains two functional domains: a N-terminal pointed (PNT) domain that is involved in protein-protein interactions with itself and other proteins, and a C-terminal DNA-binding domain. Gene knockout studies in mice suggest that it is required for hematopoiesis and maintenance of the developing vascular network. This gene is known to be involved in a large number of chromosomal rearrangements associated with leukemia and congenital fibrosarcoma.
transcription factor ETV6
, ets variant gene 6 (TEL oncogene)
, TEL oncogene
, ets variant 6
, ETS translocation variant 6
, ETS-related protein Tel1
, TEL1 oncogene
, ets domain protein